logo-loader

PreveCeutical Medical's blue scorpion venom program on track

Last updated: 16:42 24 Jan 2018 GMT, First published: 11:42 24 Jan 2018 GMT

1516812351_biotech_517925923
The team is working to sequence the extracted peptides and proteins

Health sciences group PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) updated on its peptide research and development program based on the venom of the Caribbean blue scorpion.

The firm is developing innovative preventive therapies using organic and nature identical products.

Venom from the scorpion has been shown to impact aggressive cancers, such as breast and brain.

The program is progressing on schedule through the first of its three distinct phases. Preveceutical said today.

As reported last summer, the company successfully separated several target scorpion-venom-derived peptides and proteins.

Now, the research team is working to sequence the extracted peptides and proteins to determine their amino acid fingerprint.

In addition the group is currently using high-performance liquid chromatography (HPLC) to separate the target peptides and proteins before they are sequenced.

PreveCeutical's team is also trialling the application of liquid chromatography tandem-mass spectrometry (LC-MS/MS) whereby the extracted peptides and proteins are fragmented using an ion source, and each fragment is identified by its mass-to-charge ratio.

Ultimately, this process is expected to enable the company to generate Nature IdenticalTM peptides.

PreveCeutical Medical making key advances with its Sol-gel program

Dr Harry Parekh, chief research officer for PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF), tells Proactive's Andrew Scott they've hit a number of key milestones with their Sol-gel program. He says they've now successfully optimised the conditions for extracting cannabinoids from one...

on 10/9/18